Mr. Ken d'Entremont reports

MEDEXUS AND MEDAC AGREE TO AMEND US TREOSULFAN AGREEMENT

Medexus Pharmaceuticals Inc. has recently entered into a third amendment to its February, 2021, exclusive licence agreement with medac GmbH relating to the commercialization of treosulfan in the United States.

Among other things, the third amendment extends the agreed outside date for Food and Drug Administration approval to reflect the current status of the FDA regulatory review process, and provides that, if and when the FDA accepts medac's resubmission of its new drug application for treosulfan, the parties will then negotiate in good faith any adjustments to the value of unpaid regulatory and sales-based milestone payments as may be appropriate in the then-prevailing circumstances.

Medexus continues to expect that it will take medac a period extending into first half calendar year 2024 to collect and submit the information requested by the FDA and obtain FDA acceptance of medac's treosulfan NDA resubmission. The parties will then have a specified negotiation period to agree to a further amendment with respect to any adjustments to the milestone payments. Medexus will have no obligation to make any milestone payments before the effective date of the further amendment (if any).

"We are pleased to have arrived at terms that appropriately accommodate the expected timing of medac's treosulfan NDA resubmission," commented Ken d'Entremont, chief executive officer of Medexus. "We have extended the agreed outside date for FDA approval while preserving the right and obligation to renegotiate the remaining milestone payments under the contract."

"We have also secured from medac an extension in payment terms for up to $2.5-million (U.S.) of amounts that we will incur through March 31, 2024," added Marcel Konrad, chief financial officer of Medexus. "This flexibility will allow us to better manage our cash over the remainder of our fiscal year 2024."

Additional information about the terms of the licence agreement, including a copy of the relevant documents, is included in the company's filings on its SEDAR+ profile.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy and dermatology.

We seek Safe Harbor.